

Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office: S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101 Phones: ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294 E-mail: info@indswiftlabs.com Website: www.indswiftlabs.com

CIN No. L24232CH1995PLC015553

Ref.:ISLL:CH:2017

Date: 14th September, 2017

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),

Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUB: OUTCOME OF BOARD MEETING

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, this is to inform the Exchange that the Board of Directors in its meeting held today i.e. 14th September, 2017 have taken on record inter-alia the following: -

- 1. Quarterly Un-audited Financial Results (provisional) for the quarter ended 30th June, 2017 (Copy Enclosed).
- 2. Limited Review Certificate of Statutory Auditors of the Company (Copy Enclosed).

You are requested to kindly take a record of the same.

Thanking you

IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA

GM-CORPORATE AFFAIRS &

COMPANY SECRETARY

Encl.: As above

Works: Barwala Road, Vill. Bhagwanpur, Near Dera Bassi, Distt. Mohali (Punjab) Tel.: + + 91-1762-281072, Telefax: ++91-1762-281073

IND SWIFT LABORATORIES LTD.

Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160 101
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017

Purificulars Covarier Ended 30.04.2017 Quarter Ended 30.04.2017 Qua	Perficulars Ouwrier Ended 30.06.2017 Ouwrier Ended 30.06.2017 Ouwrier Ended 30.06.2017 Ouwrier Ended 30.06.2017 Order Income town Operations: Income town Operations: Other Income 19626988 1962698 1962698 1962698 1962698 1962698 1962698 1962	CIN L24232CH	1995PLC015553	
UnAustited UnAustited UnAustited UnAustited UnAustited UnAustited UnAustited UnAustited UnAustited Process to Construct Constructions (Constructions) (Constru	Income from Operations: UnAuditied UnAu			(Rs. In Lacs
	income from Operations:	Particulars	Quarter Ended 30.06.2017	Quarter Ended 30.06.2016
Streeting the magnetions 14640 as 17820	Revenue from speatores 1946-80 177 Prior Income 490-40 176 Prior Income 490-40 176 Prior Revenue 1946-83 181 Prior Revenue 1946-83 181 Prior Revenue 1975-84 1975-84 181 Prior Revenue 1975-84 1975-84 181 Prior Revenue 1975-84 1		UnAudited	UnAudited
interinctions Applications A	John Fronze 480-0 16848-39 189 TREPINSES 1997-841 500 500 ct of Materials Contaurined 9977-841 500 700 ct of Materials Contaurined 9977-841 700 ct of Materials Contaurined 9977-841 700 ct of Materials Contaurined 9977-841 9977-842 9978-997-997-997-997-997-997-997-997-997			
obst Revenue 1966-55 1969-65 1	Out of Materials Consumed Cost of Materials Consumed (Increase) Joseph Services (In		16408.99	17992.94
PREMISES 1997,841 1998,950 1997,841 1998,950 1997,841 1998,950 1997,841 1998,950 1997,841 1998,950 1997,841 1998,950 1997,950	APENDESS: Purpose of loted infrase Currently of stock infrase Purpose of stock infrase Purpose of stock infrase Purpose of stock infrase Currently of stock infrase Currently of stock Staff cost Staff c		436.40	392.24
XPENSES. Quantity and spoke finished Quantity of spoke f	XPENSES:	otal Revenue	16845.39	18385.18
Purpose of stock in Trade	Puchase of slock infrase D.D.D.	XPENSES:		
Pubmisson Floring Fl	Purchase of sock infrade (Increase) (decrease in FO.WPP & stock in trade 303-40 e Self cost 1944-63 171 Transact Costs 1944-63 2208-64 22	Cost of Materials Consumed	9675 41	9268 86
(Increase) Stortese in F.G.VIPF & stock in trade 1915.55 1779-99	(increase) (discrease in FQ,WIP & stock in trade \$30.00 In Section 1 1945,58 \$30.10 In Presence Codes 2008.82 200.40 2019.40 200.40 2	Purchase of stock inTrade		
Silef ceet Silef	Saft cost. 1945.55 17 Finance Costs 2098.82 22 22 Cappresiation 2008.80 2208.60 27 Comer expenditure 3019.91 39 3019.91 3019.9	(Increase) /decrease in FG WIP & stock in trade		
Finance Costs Speried September 1 2008-40 191	Finance Costs Speciation 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 2004.00 (16 2004.00) (17 2004.00) (17 2004.00) (18 2004.00) (18 2004.00) (18 2004.00) (18 2004.00) (18 2004.00) (18 2004.00) (2004.00			
Depreciation 2006.00 3168.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60 3169.61 3265.60	Depreciation 2004-00 23 Comer expenditure 2014-00 30 19 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 3 19 3 3 19 3 3 19 3 3 19 3 3 19 3 3 19 3 3 19 3			
Context expensions 1919-1917 1920-1917 19	Coher expenditure TOTAL EXPENSES 1913.47 200 CORTICIOSA Defore exceptional , extraordinary items and Tax (2294.08) (16 Control (1605.08) (176 Control (1605.08) Control (1605.08) (176 Control (1605.08) Control			
OTAL EXPENSES 1919.47 2006.4 (19284.08) (1973.2 (1973.2 (1973.2) (1973.2 (1973.2) (1973	OTAL EXPENSES 1919.847 ORTIOR(1059) Select exceptional, extraordinary items and Tax (2284.08) (150 control interesting the selection of th		2206.40	2188.40
rotitiosa) before exceptional, extraordinary items and Tax (2294.09) (1673.2) (1673	rofit(loss) before exceptional , extraordinary items and Tax (2294.08) [19 recordinary items (2294.08) [19 recordinary items and Tax (2294.08) [19 rec		3019.91	3625.85
roffil(fee) before exceptional, extraordinary items and Tax (2294,08) (1673,20) (1673	rofficios) before exceptional , extraordinary items and Tax (2294.08) (16 conceptional lams (2294.08) (16 conficios) before extraordinary items and Tax (2294.08) (16 conficios) before extraordinary items and Tax (2294.08) (16 conceptional lams (229		19139.47	20058.44
rofit(iess) before extraordinary items and Tax (2294.08) (1673.28 IX Expenses: (10Current Tax 0.00 0.00 (10Current Tax 0.00	Internationary items (2294.08) (18 Attracedisary items (2294.08) (19 Attracedisary items (2294.08) (10 Attracedis	rofit(loss) before exceptional , extraordinary items and Tax	(2294.08)	(1673.26
Axional company tenses (2294.08) (1673.28 AX Expenses: (1)Courrent Tax (2294.08) (1673.28 AX Expenses: (1)Courrent Tax (2294.08) (1673.28 (1)Courrent Tax (2294.08) (1000 0.00 (2000 0.0	Taxordiany piems (2294.09) (168 Tax Expenses: (2294.08) (166 Tax Expenses: (190.urrent Tax		0.00	. 0.00
Available Avai	Attracediary Intense (2294.08) (168 at Expenses: (2294.08) (168 at Expenses: (2294.08) (168 at Expenses: (2294.08) (168 at Expenses: (2294.08) (168 at Chalf Intelligents (1694) at Chalf Intelligents (1694) at Chalf Intelligents (1694) at Chalf Intelligents (1694) at Expenses	rofit(loss) before extraordinary items and Tax	(000.00)	
(2294.08) (1673.28 ax Expenses :- (1)Current Tax 0.00 0.00 1.	(1)Current Tax. (2294.08) (1)Current Tax. (2000 concerns a diclustment of Previous Year (2000 concerns a diclustmen	xtraordinary items		(1673.26 0.00
(i)Current Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	(1)Current Tax 0,00 tat Credit Entitlement (2)Centerned Tax 0,00 total Credit Entitlement (2)Centerned Tax 0,00 troff (4)/ Loss (-) from discountinuing operations (2294,08) (16 tax Expenses of discountinuing operations (2294,08) (16 tax Expenses of discountinuing operations (2294,08) (16 ten Comprehensive Income (1)Centerned Tax 0,00 ten Comprehensive Income (1)Centerned Tax 0,00 ther Comprehensive Income / Loss for the period, net of Tax 0,00 ther Comprehensive Income / Loss for the period, net of Tax 0,00 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Comprehensive Income / Loss for the Period (2294,08) (16 ther Capital/Face Value of Rs. 10/- per Share) service excluding revisuation reserved. (2594,08) (16 tax Details (1	rofit(loss) before Tax		
Command Comm	Comparison Com	ax Expenses :-	(2294.08)	(1673.26
come Tax adjustment of Previous Year that Credit Emindent (2)Defirered Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	Comparison Com	(1)0		
at Credit Entitlement 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	at Credit Entitlement 2,006 (2)20efferred Tax 0.00 control (+) Loss (-) for the period from continuing operations (2294.08) (16 control (-) Loss (-) from discountinuing operations 0.00 at Experience of discountinuing operations 0.00 at Experience of discountinuing operations 0.00 control (-) Loss (-) from discountinuing operations (0.00 at Profit (-) Loss (-) from discountinuing operations (0.00 at Profit (-) Loss (-) from discountinuing operations (0.00 at Profit (-) Loss (-) from discountinuing operations (0.00 at Profit (-) Loss (-) from discountinuing operations (-) (-) (-) (-) (-) (-) (-) (-) (-) (-)		0.00	0.00
2)Defered Tax Completed Tax Comple	2)Defered Tax Confit (*Y Loss (.) for the period from continuing operations (2234.88) (16 confit (*Y Loss (.) from discountinuing operations Ac Expense of discountinuing operations Confit (*Y Loss (.) from discountinuing operations Confit (*Y Loss (.) from discountinuing operations Confit (*Y Loss (.) from discountinuing operations (Confit (*Y Loss (.) from discountinuining operations (Confit (*Y Loss (.) from discountinuing oper			0.00
coffit (+)*Loss (-)* for the period from continuing operations Cay 4,08 (1573.26	coff (+)/ Loss (-) for the period from continuing operations coff (+)/ Loss (-) from discountinuing operations (0.00	0.00
coff (+)*Loss (-)* from discountinuing operations 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	coff (+)/Loss (-) from discountinuing operations x Expense of discountinuing operations 0.00 x Expense of discountinuing operations 0.00 coff (+)/Loss (-) from discountinuing operations 0.00 coff (+)/Loss (-) from discountinuing operations 0.00 condition (+)/Loss (-) from discountinuing operations (2294.08) (188 ther Comprehensive Income Items that will be reclassified to P/L A/C 0.00 Items that will be reclassified to P/L A/C 0.00 Items that will be reclassified in P/L A/C 0.00 1.61 Items that will be reclassified in P/L A/C 0.00 Items that will be reclassified in P/L A/C 0.00 Items that will be reclassified in P/L A/C 0.00 Items that will be reclassified in P/		0.00	0.00
ax Expense of discountinuing operations (100 000 000 000 000 000 000 000 000 00	ax Expense of discountinuing operations (700) or (11) Chron discountinuing operations (After Tax) (9.00) or (11) Chron (1			(1673.26
rofit (F) Loss () from discountinuing operations(after Tax) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	rofit (F) Loss (-) from discountinuiting operations(after Tax) (2294.08) (168 ther Comprehensive Income Name that will not be reclassified to P/L A/c	ay Expense of discounting operations		
ther Comprehensive Income Illems that will not be reclassified in P.P. A/c	ther Comprehensive Income Items that will not be reclassified to P/L A/c			0.00
ther Comprehensive Income Items that will not be reclassified to PIL A/c 0.00 0.00 0.00 Items that will not be reclassified to PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Items that will be reclassified into PIL A/c 0.00	ther Comprehensive Income) Items that will not be reclassified to P/L A/c Items that will not be reclassified to P/L A/c Items that will not be reclassified to P/L A/c O.00 Items that will be reclassified to P/L A/c O.00 that Stat will be reclassified to P/L A/c O.00 that Comprehensive Income / Loss for the period , net of Tax O.00 tal Comprehensive Income / Loss for the period , net of Tax O.00 tal Comprehensive Income / Loss for the period , net of Tax O.00 tal Up Equity Share Capital/Face Value of Rs. 10/- per Share) aid up Equity Share Capital/Face Value of Rs. 10/- per Share) aid up Equity Share Capital/Face Value of Rs. 10/- per Share) 4473.96 4			
Illems that will not be reclassified to PIL A/C Libers that will not be reclassified to PIL A/C Libers that will not be reclassified to PIL A/C Liber Comprehensive Income / Loss for the period, net of Tax	Items that will not be reclassified to PL A/C Items that will be reclassified into PL A/C Items that will be r	er i folicit Cood/ for the period	(2294.08)	(1673.26
Items that will not be reclassified to PIL AIC Items that will not be reclassified to PIL AIC Items that will be reclassified to PIL AIC O.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	Items that will not be reclassified to PL. A/c ther Comprehensive Income / Loss for the period, net of Tax the Comprehensive Income / Loss for the period, net of Tax did up Equity Share Capital(Face Value of Rs. 10/- per Share) aid up Equity Share Capital(Face Value of Rs. 10/- per Share) serve excluding revaluation reserves PS (of Rs. 10/- each) (Not annualised) Basic Share Sha	ther Comprehensive Income		
items that will be reclassified into PL Arc ther Comprehensive Income / Loss for the period, net of Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	Liters that will be reclassified into PIL AC 1.00 that Comprehensive Income / Loss for the period , net of Tax 2.00 that Comprehensive Income for the Period 2.224.08) (16 2.224.08) (I tems that will not be reclassified to P/I. A/c	0.00	
ther Comprehensive Income / Loss for the period , net of Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	ther Comprehensive Income / Loss for the period , net of Tax 0.00 otal Comprehensive Income for the Period (2294.08) (16 aid up Equity Share Capital(Face Value of Rs. 10/- per Share) 4473.96 serve excluding revaluation reserves 18,372.12 18,81 Sasic (5,13) Diluted (5,13) Diluted (5,13) Otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th , So 17. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ulses, 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not unaudatory as per SEBI circuler date 05th July 2016. Under the provisions of the Company Law Board. The Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D. 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided.) items that will be reclassified into P/L A/c		
aid up Equity Share Capital(Face Value of Rs. 10/- per Share) aid up Equity Share Capital(Face Value of Rs. 10/- per Share) A473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 585 (of Rs. 10/- each) (Not annualised) Basic Diluted (5.13) (4.06 (5.13) (4.06 (5.13) (4.06 (5.13) (4.06 (5.13) (4.07 (5.13) (4.07 (5.13) (4.07 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (4.08 (5.13) (5.13) (5.13) (5.13) (5.13) (6.08 (5.13) (6.08 (5.13) (6.08 (5.13) (6.08 (5.13) (6.08 (5.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.08 (6.13) (6.13) (6.08 (6.13) (6.10) (6.13) (6.10) (6.13) (6.10) (6.13) (6.10) (6.13) (6.10) (6.13) (6.10) (6.13) (6.10) (6.13) (6.10) (6.1	taid up Equity Share Capital(Face Value of Rs. 10/- per Share) 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4473.96 4873.96 498.97			
aid up Equity Share Capital (Face Value of Rs. 10/- per Share) eserve excluding revaluation reserves 18,372.12 18,887.80 28 (of Rs. 10/- each) (Not annualised) Basic (5,13) (4,06 (5,13) (1,08 (1	aid up Equity Share Capital(Face Value of Rs. 10/- per Share) 4473.96 4473.96 4473.96 4473.96 458.10/- each) (Not annualised) Basic (5.13) Diluted (5.13) Diluted (5.13) Dives: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,So. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) usles, 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D. 20.99.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.			0.00
eserve excluding revaluation reserves 18,372.12	eserve excluding revaluation reserves 18,372.12 18,88	otal Comprehensive income for the Period	(2294.08)	(1673.26
eserve excluding revaluation reserves 18,372.12	eserve excluding revaluation reserves 18,372.12 18,88	aid up Equity Share Capital/Face Value of Rs. 10/, per Share)	4470.00	
PS (of Rs. 10/- each) (Not annualised) Basic (5.13) (4.06 Diluted (5.13) (4.06 Otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,Sept 2017. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 20.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Basic (5.13) Diluted (5.13) Diluted (5.13) Diluted (5.13) Otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th , S 017. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules , 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	eserve excluding revaluation reserves		
Basic Diluted (5.13) (4.06 Diluted (5.13) (5.13) (4.06 Otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,Sept 2017. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable that statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nearly as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 1.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Diluted (5.13) Otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th , S ot 7. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017 ,with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) cules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent application application of the companies act 2015 and other recognised accounting practices and policies to extent application and the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Diagnostic provisions of the Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	PS (of Rs. 10/- each) (Not annualised)	10,372.12	18,887.80
otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,Sept 2017. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 20.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment. In Company is exclusively in the Pharmaceutical Business segment.	otes: - The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,S out. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not handatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Basic	(5.13)	(4.08
The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,Sept 2017. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) 2018; 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable 13th 13th 13th 13th 13th 13th 13th 13th	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,S 017. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not need to provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Diluted		
The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,Sept D17. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,SD17. The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.		(6.10)	(4.00
The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Example 1.00.00.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	otes: -		
The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules, 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31,03,2017 as the same is not nearly provided. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09,2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The previous period figures have been re-grouped and re-arranged wherever necessary. The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) utiles, 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	. The above results have been reviewed by the Audit Committee and approve	ed by the Board of Directors at their respective	Meetings held on 14th ,Sept
The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The company has first time adopted IND AS with effect from 1st April 2017, with transition date of 1st April 2016. The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Do.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	. The previous period figures have been re-grouped and re-arranged wherever	er necessary.	
The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not near the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The unaudited standalone financial results have been prepared by the company in accordance woth the companies (Indian accounting standards) ules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applic The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not landatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The company has first time adopted IND AS with effect from 1st April 2017 .	with transition date of 1st April 2016	
Liles 2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable. The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Liles ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent application application of the statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not nandatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The unaudited standalone financial results have been prepared by the community	nany in accordance with the companies (Indian	coccupting standards)
The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not handatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not handatory as per SEBI circuler date 05th July 2016. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	iles 2015 (IND AS) prescribed under section 133 of the companies act 2013	and other recognised, accounting prostings	decounting standards)
Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Intercept of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	The statement does not include IND-AS compliant regults for the proceeding	and other recognised accounting practices an	u policies to extent applicable
Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 0.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, D.0.9.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits. There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	pandatory as per SERI circular data 05th July 2046	y quarter and imancial year ended 31.03.2017 a	is the same is not
There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment. for Ind-Swift Laboratories Limited ate: 14.09.2017	There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment. For Ind-Swift Laboratorea Lines Control of the same has been provided.	Under the provisions of the Companies Act, 1956, the Company has got its	Fixed Deposit Scheme restructured vide its order	er No. C.P 27/01/2013, Dated
AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment. For Ind-Swift Laboratore Limited ace: Chandigarh late: 14.09.2017	AAP to IND AS, hence no comparison of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment. Aor Ind-Swift Laboratories Lines Constitution of the same has been provided. The Company is exclusively in the Pharmaceutical Business segment.	There is no impact on Net profit /Loss, total Comprehensive Income or any o	8 8	(5)
ace : Chandigarh late: 14.09.2017 Ror Ind-Swift Laboratories Limited N R Munja	ace : Chandigarh	AAP to IND AS, hence no comparison of the same has been provided.		Tom the previous indian
ace : Chandigarh ate: 14.09.2017 N R Munja	ace: Chandigarh	The company is exclusively in the Frialinaceutical business segment.		
ace : Chandigarh ate: 14.09.2017 N R Munja	ace: Chandigarh			1
ace : Chandigarh ate: 14.09.2017 N R Munja	ace: Chandigarh			For Ind-Swift Laboratories Limited
late: 14.09.2017 N R Munja	14.00.0047			MAR Satte
IV IV Mulija	ate: 14,09,2017			I ICUI ZEL IVA
		ate: 14.09.2017		N R Munjal

S.C.O. 819-20, Sector-22 A, Chandigarh 160 022 Phone: 0172-2575761, 2575762

Mobile: 9316112404

Email:jainassociates1968@gmail.com Suresh.c.pat@hotmail.com

LIMITED REVIEW

The Board of Directors Ind-Swift Laboratories Ltd. S.C.O. 850, NAC Manimajra Chandigarh

We have reviewed the accompanying statement of unaudited standalone financial results of Ind-Swift Laboratories Ltd for the Quarter ended 30.06.2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data—and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express such an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards, IND AS prescribed under section 133 of companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that is contains any material misstatement.

FOR JAIN & ASSOCIATES Chartered Accountants

(Regd No.:001361N)

Od Ac Partner

Membership No 10194

Place: Chandigarh Date: 14.09.2017